Welcome to OncoStem

At OncoStem, we develop innovative prognostic tests that assess aggressiveness of tumours based on in-depth knowledge of tumour biology, to identify the unique characteristics of cancer recurrence risk. Since 2011, our vision is to empower the doctors with evidence-based treatment plans with our smart prognostic tests. These actionable tests help the physicians in formulating a customized treatment plan by understanding the tumour biology. Robust research is ongoing in our laboratory to develop novel tests for other cancers.

CanAssist Breast

CanAssist Breast is our flagship product which uses a proprietary Artificial Intelligence-based statistical model to identify the patient's risk of breast cancer recurrence over five years. It is a prognostic test that analyses the critical biomarkers in the tumour and classifies the patients into "low- risk" or "high-risk" for cancer recurrence. Based on the risk scores, the oncologists can frame an informed and personalized treatment plan wherein the low-risk patients can safely avoid chemotherapy.

Choose the right treatment with CanAssist Breast by weighing the risks and benefits of chemotherapy.

WHAT WE DO


AI-driven biomarker-based prognostic tests for cancer
Individualized cancer therapy customized to each patient’s needs
Personalized treatments to improve quality of life
First test to be validated on Indian patients
Trusted by 300+ oncologists across South Asia
"Best Innovation-Risk Assessment" by NASSCOM

ONCOSTEM FEATURES


CANASSIST BREAST

KNOW MORE ABOUT
BREAST CANCER

SUPPORT PROGRAMS FOR
BREAST CANCER PATIENTS

THE SCIENCE
BEHIND CANASSIST
BREAST

SCIENTIFIC
PUBLICATIONS

LATEST NEWS
AND EVENTS

ONCOSTEM FEATURES


CANASSIST BREAST

THE SCIENCE &
BEHIND CANASSIST
BREAST

SCIENTIFIC
PUBLICATIONS

KNOW MORE ABOUT
BREAST CANCER

SUPPORT PROGRAMS FOR
BREAST CANCER PATIENTS

LATEST NEWS
AND EVENTS

LATEST NEWS
AND EVENTS

TESTIMONIALS

What oncologists and cancer patients are saying about CanAssist Breast

Want to know about your recurrence risk?

to personalize your cancer treatment and reduce the risk & side effects of chemotheraphy